Teleflex Reports Strong Revenue Growth Amid Challenges

Teleflex ( (TFX) ) has released its Q3 earnings. Here is a breakdown of the information Teleflex presented to its investors.

Teleflex Incorporated is a global provider of medical technologies, specializing in areas such as anesthesia, emergency medicine, interventional cardiology, and surgical and urology products. The company is known for its diverse portfolio of trusted brands and its commitment to improving healthcare outcomes.

In its latest earnings report, Teleflex announced a significant increase in third-quarter revenue, with GAAP revenue reaching $913 million, marking a 19.4% rise from the previous year. Despite this growth, the company reported a GAAP diluted EPS loss from continuing operations of $(9.24), a stark contrast to the $2.36 EPS from the prior year. Adjusted diluted EPS, however, showed an improvement, reaching $3.67 compared to $3.49 in the previous year.

Key financial highlights include a notable performance in the EMEA region, which saw a 55.9% increase in reported revenue. The Interventional segment also experienced substantial growth, with a 77.8% increase in revenue. However, the company faced challenges in its Interventional Urology and OEM segments, which saw declines of 13.9% and 2.6%, respectively. The report also highlighted a $403.9 million goodwill impairment charge related to the Interventional Urology North America unit, reflecting deteriorating market conditions.

Looking ahead, Teleflex has narrowed its full-year 2025 revenue growth guidance on a GAAP basis to a range of 9.10% to 9.60%. The company remains focused on its strategic initiatives, including the integration of the Vascular Intervention business and the potential sale of NewCo. Management expressed confidence in executing its strategy to drive shareholder value despite the challenges faced in certain segments.